Long-term multicenter observational study of Alflutop in Russia: use in elderly patients with osteoarthritis at various sites (report 5)

Osteoarthritis (OA) is one of the most significant medical and social problems due to a steady increase in its incidence and associated disability rates.
Objective. To evaluate the efficacy of Alflutop in elderly patients with osteoarthritis (OA) of the knee (KOA) and/or hip (HOA) and/or with low back pain (LBP).
Material and methods. This prospective, multicenter, cohort observational study was conducted in 163 clinical centers across 58 cities of the Russian Federation. Of 22,525 enrolled patients with OA at various sites and/or LBP, 10,927 were ≥60 years and comprised the analysis population. Alflutop was prescribed as part of routine care per physician decision or purchased by patients. Study duration was 20–31 days with two visits. Regimens were either 1 mL intramuscularly (IM) for 20 consecutive days or 2 mL IM every other day totaling 10 injections. Efficacy was assessed by time to clinical effect (patient-reported pain reduction), change in pain intensity during movement in the index joint and/or LBP on a visual analogue scale (VAS), health-related quality of life by EQ-5D, and patient global assessment (PGA) on VAS. Treatment adherence, need for nonsteroidal anti-inflammatory drugs, and treatment satisfaction (VAS) were recorded.
Results and discussion. Primary efficacy parameters showed pronounced improvement over the treatment course. In patients with KOA (n=6138), median pain reduction (VAS) was 57.1 [33.3; 75] %, median improvement in PGA (VAS) was 40 [14.3; 100] %, and treatment satisfaction was 80 [60; 90] mm. In most patients with HOA (n=4377), substantial improvement was observed: median pain decreased by 50 [33.3; 75] %, PGA increased by 40 [14.3; 100] %, and treatment satisfaction was 80 [60; 90] mm. Among patients with hand OA (n=1346), median VAS improvement was 60 [37.5; 80] %. Marked positive dynamics were recorded for EQ-5D and PGA: from 0.59 [0.52; 0.69] to 0.82 [0.73; 1.0] points (p<0.0001) and from 50 [40; 67] to 80 [70; 90] mm (p<0.0001), respectively. In patients with nonspecific LBP (n=5135), pain decreased and PGA improved: median pain reduction was 57.1 [37.5; 75] % and PGA increased by 50 [14.3; 100] %. A good response (≥50% pain reduction) was observed in 65.1% of cases.
Conclusion. This observational study supports the symptomatic effect of Alflutop and its appropriateness for use in patients aged ≥60 years with OA of various sites and with LBP.

1. Im GI, Kim MK. The relationship between osteoarthritis and osteoporosis. J Bone Miner Metab. 2014 Mar;32(2):101-9. doi: 10.1007/s00774-013-0531-0.

2. GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7.

3. Xie X, Zhang K, Li Y, et al. Global, regional, and national burden of osteoarthritis from 1990 to 2021 and projections to 2035: A cross-sectional study for the Global Burden of Disease Study 2021. PLoS One. 2025 May 27;20(5):e0324296. doi: 10.1371/journal.pone.0324296.

4. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.

5. Long H, Liu Q, Yin H, et al. Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022 Jul;74(7):1172-1183. doi: 10.1002/art.42089.

6. Ackerman IN, Buchbinder R, March L. Global Burden of Disease Study 2019: an opportunity to understand the growing prevalence and impact of hip, knee, hand and other osteoarthritis in Australia. Intern Med J. 2022 Sep 16. doi: 10.1111/imj.15933. Online ahead of print.

7. Wan J, Qian X, He Z, et al. Epidemiological trends of hand osteoarthritis from 1990 to 2019: Estimates from the 2019 Global Burden of Disease study. Front Med (Lausanne). 2022 Dec 12;9:922321. doi: 10.3389/fmed.2022.922321. Collection 2022.

8. Leyland KM, Gates LS, Sanchez-Santos MT, et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res. 2021 Mar;33(3):529-545. doi: 10.1007/s40520-020-01762-2.

9. Wang H, Bai J, He B, et al. Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studies. Sci Rep. 2016 Dec 22:6:39672. doi: 10.1038/srep39672.

10. Rahman MM, Kopec JA, Cibere J, et al. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. BMJ Open. 2013 May 14;3(5):e002624. doi: 10.1136/bmjopen-2013-002624.

11. Xie Y, Zhou W, Zhong Z, et al. Metabolic syndrome, hypertension, and hyperglycemia were positively associated with knee osteoarthritis, while dyslipidemia showed no association with knee osteoarthritis. Clin Rheumatol. 2021 Feb;40(2):711-724. doi: 10.1007/s10067-020-05216-y.

12. Chen C, Guo-Feng B, Guanhua X, et al. Altered Wnt and NF-κB Signaling in Facet Joint Osteoarthritis: Insights from RNA Deep Sequencing. Tohoku J Exp Med. 2018 May; 245(1):69-77. doi: 10.1620/tjem.245.69

13. Buse E, Dumitriu B, Olariu L, et al. Cellular and Molecular Activity of a Standardized Small Sea Fish Extract in an Experimental Model of Primary Human Cartilage Cells. Ro J Rheumatol. 2018;27(1):23-31. doi: 10.37897/RJR.2018.1.4

14. Olariu L, Dumitriu B, Craciun L, et al. The in vitro influence of a pharmaceutically active small sea fish extract on apoptosis and proliferation mechanisms amplified by inflammatory conditions. Farmacia. 2018;55(3): 524-29.

15. Groppa L, Mynzatu I, Karasava M, et al. The effectiveness of Alflutope in patients with deforming osteoarthritis. Klinicheskaya revmatologiya. 1995;(3):20-22. (In Russ.).

16. Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Jul;12(7):412-20. doi: 10.1038/nrrheum.2016.65.

17. Olariu L, Dimitriu B, Manuela Ene D, et al. In vitro effect of Alflutop on the mechanisms of osteoarthritis development. Vestnik Akademii rumynskikh uchenykh. 2017;(6)1:82-99. (In Russ.).

18. Karateev AE. Bioactive concentrate from small sea fish: Evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(4):111-24. (In Russ.). doi: 10.14412/1996-7012-2020-4-111-124.

19. Lila AM, Alekseeva LI, Taskina EA, Kashevarova NG. Alflutop Russian longitudinal multicentre observational study: preliminary results (message 1). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023;17(2):57-64. (In Russ.). doi: 10.14412/19967012-2023-2-57-64

20. Lila AM, Taskina EA, Alekseeva LI, Kashevarova NG. Multicenter Longitudinal Observational Study Pharmaceuticals Alflutop in Russia (message 2). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023;17(4):75-85. (In Russ.). doi: 10.14412/1996-7012-2023-4-75-85

21. Lila AM, Karateev AE, Alexeeva LI, at al. Alflutop Russian longitudinal multicenter observational study: use in patients with chronic back pain (message 3). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024;18(1):70-75. (In Russ.). doi: 10.14412/1996-7012-2024-1-70-75.

22. Taskina EA, Alekseeva LI, Kashevarova NG, Lila AM. Long-term multicenter observational study of the drug Alflutop in Russia: use in patients with knee osteoarthritis (report 4). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024;18(4):80-88. (In Russ.). doi: 10.14412/1996-7012-2024-4-80-88

23. Alekseeva LI, Sharapova EP, Taskina EA, et al. Multicenter double-blind randomized placebo-controlled trial of the symptom- and structuremodifying effect of Alflutop in patients with knee osteoarthrosis. Communication 1. Evaluation of the symptom-modifying effect of the drug. Nauchno-Prakticheskaya Revmatologia. 2013;51(5):532-538. (In Russ.).

24. Alekseeva LI, Sharapova EP, Taskina EA, et al. A multicenter, blind, randomized, placebocontrolled study of the symptom- and structuremodifying effect of Alflutop in patients with knee osteoarthritis. Report 2: The assessment of the struc ture-modifying effect of the drug. Nauchno-Prakticheskaya Revmatologia. 2014; 52(2):174-177. (In Russ.).